Oxford Immunotec Announces Availability of the T-SPOT.CMV Test in the United States
(Thomson Reuters ONE) -
OXFORD, U.K. and MARLBOROUGH, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- Oxford
Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics
company focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions, today announced the availability in
the United States of a new test that measures the strength of a patient's
cellular immune response to cytomegalovirus (CMV). This T-SPOT(®).CMV test is
available as a Laboratory Developed Test from the Company's CLIA-certified and
CAP accredited service laboratory.
"We are pleased to provide physicians the T-SPOT.CMV test earlier than our
previously announced timeline," said Dr. Peter Wrighton-Smith, Chief Executive
Officer of Oxford Immunotec. "While we are enthusiastic about the potential
clinical utility and economic value that the T-SPOT.CMV test may provide in
transplant medicine, we are taking a measured approach to market introduction as
we await the results of our PROTECT and REACT clinical trials. We continue to
expect full commercial launch in the second half of 2016."
T cell immunity against CMV is a factor in controlling viral latency and
susceptibility to CMV disease. CMV can affect individuals with weaknesses in
their T cell response and it is therefore an important and common cause of
morbidity and mortality in solid organ and hematopoietic stem cell transplant
recipients. The T-SPOT.CMV test measures the strength of T cell responses to CMV
specific antigens. The T-SPOT.CMV test has the potential to assist clinicians
with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV
disease.
The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology
platform. The new test will be performed at Oxford Diagnostic Laboratories in
Memphis, TN, where validation was performed. The test results will be available
to customers within two days of receipt of a whole blood sample. The T-SPOT.CMV
test builds on Oxford Immunotec's capabilities in T cell measurement technology,
and is the first in a series of planned new products intended to help transplant
patients and physicians manage immune regulated conditions.
The T-SPOT.CMV test is pending approval in California, New York and Florida.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the management
of immune-regulated conditions. The Company's first product is the T-SPOT.TB
test, which is used to test for tuberculosis infection. The T-SPOT.TB test has
been approved for sale in over 50 countries, including the United States, where
it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well
as Japan and China. The T-SPOT.CMV test is the Company's second product and the
first of three products we intend to launch for the transplantation market.
Overall, the Company has six active development programs, each of which
leverages our T cell and innate immune measuring technology. The Company is
headquartered near Oxford, UK and in Marlborough, MA. Additional information can
be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec(at)westwicke.com
--------------------------------------------------------------------------------
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
[HUG#1908126]
Unternehmensinformation / Kurzprofil:
Datum: 31.03.2015 - 22:17 Uhr
Sprache: Deutsch
News-ID 382665
Anzahl Zeichen: 4736
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 186 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Announces Availability of the T-SPOT.CMV Test in the United States"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
